A Phase 1b/2 Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer.

Brief description of study

You can participate in this study if you are diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care chemotherapy in participants with metastatic colorectal cancer (Ph2 cohorts), and to assess the recommended phase 2 combination dose of amivantamab when added to standard-of care chemotherapy (Ph1b cohorts).


Clinical Study Identifier: s22-00147
ClinicalTrials.gov Identifier: NCT05379595


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.